Lisa Bodei, MD, PhD
Nuclear Medicine Physician
Titles
Director of Targeted Radionuclide Therapy
Clinical Expertise
Nuclear Medicine; Molecular Imaging and Targeted Radionuclide Therapy; PET
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Bodei accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 212-639-5387 Office Phone
- Speaks English and Italian
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, University of Pisa (Italy); PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen (Netherlands)
Residencies
School of Specialization in Nuclear Medicine, University of Pisa (Italy)
Fellowships
Nuclear Medicine Division, European Institute of Oncology (Milan, Italy)
Board Certifications
Nuclear Medicine (US); Nuclear Medicine (Italy)
I am a nuclear medicine physician who has extensive experience and broad expertise in therapeutic and diagnostic applications of nuclear medicine in oncology.
Read more
My past clinical and research experience has been multifaceted, and includes combining the therapeutic and diagnostic components of nuclear medicine, which is referred to as theranostics. From the therapeutic perspective, my special expertise is in the development of peptide receptor radionuclide therapy (PRRT) of gut and lung neuroendocrine tumors, including special investigational and molecular translational analyses to facilitate their diagnosis and therapy. In addition, I have substantial experience with radioiodine therapy of differentiated thyroid cancer and hyperthyroidism. I also have expertise in the utilization of systemic radioimmunotherapy for loco-regional disease, brain tumors, ovarian carcinoma, and non-Hodgkin lymphoma.
In the diagnostic arena my expertise includes a broad range of diagnostic endocrine applications in nuclear medicine such as receptor scintigraphy, 68Ga-octreotide PET/TC, 18FDG-PET/CT in oncology, radio-immuno-scintigraphy, and sentinel node scintigraphy.
I am the author or co-author of more than 100 peer-reviewed publications, and serve on the editorial boards of several scientific journals including the Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.
Awards and Honors
- Most Distinguished Italian Researcher Award, for clinical research activities on neuroendocrine tumors and multiple endocrine neoplasia, Italian Association of Neuroendocrine Tumors, NPO, (2012)
- "For Women by Women" Award, Italian Association for Neuroendocrine Tumors, NPO (2012)
- Award for the Scientific Contribution to the European Congress of Endocrinology (2013)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all Molecular Imaging and Therapy Service doctors
Clinical Trials
- Clinical Trials Investigated by Dr. Bodei
- A Phase I Study of 177Lu-DOTA-EB-TATE in People with Advanced Neuroendocrine Cancers
- A Phase III Study Comparing 177Lu-PSMA-617 plus Standard of Care versus Standard of Care Alone to Treat Metastatic Hormone-Sensitive Prostate Cancer
- Clinical Trials Co-Investigated by Dr. Bodei
- A Study Comparing Lutetium Edotreotide with Standard Treatments in People with Digestive Neuroendocrine Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Bodei’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lisa Bodei discloses the following relationships and financial interests:
-
Advanced Accelerator Applications USA
Provision of Services (uncompensated) -
American Board of Nuclear Medicine
Provision of Services (uncompensated) -
Clinical Imaging
Provision of Services (uncompensated) -
European Journal of Nuclear Medicine and Molecular Imaging
Provision of Services (uncompensated) -
European Neuroendocrine Tumor Society
Provision of Services (uncompensated) -
European Society for Medical Oncology (ESMO)
Provision of Services (uncompensated) -
Ipsen Pharma
Provision of Services (uncompensated) -
Journal of Neuroendocrinology
Provision of Services (uncompensated)
-
Journal of Nuclear Medicine
Provision of Services (uncompensated) -
National Cancer Institute
Provision of Services (uncompensated) -
Neuroendocrine Tumor Research Foundation
Provision of Services (uncompensated) -
POINT Biopharma Global Inc.
Provision of Services (uncompensated) -
Precirix NV
Provision of Services (uncompensated) -
Society of Nuclear Medicine and Molecular Imaging
Provision of Services (uncompensated) -
The Quarterly Journal of Nuclear Medicine and Molecular Imaging
Provision of Services (uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].